Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: Luymes CH, Poortvliet RKE, van Geloven N, et al. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med. 2018;16(1):5.
The prescription of cardiovascular drugs in primary prevention may be challenging due to the risk of adverse drug reactions overcoming the benefits in a population with low cardiovascular risk.1 The impact of drug deprescription in this context is still unknown.
This was a multicentric, open-label, cluster randomised controlled trial comparing the effect of the deprescription of cardiovascular drugs versus usual care.2 The trial included patients aged between 40 and 70 years with a low risk of cardiovascular events treated with antihypertensive drugs or lipid-lowering drugs for more than 1 year. The primary outcome was the difference in …
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.